Volitionrx limited announces full fiscal year 2021 financial results and business update

Conference call to discuss financial and operational results scheduled for thursday, march 31, at 8:00am u.s. eastern time ·        executed global licensing and supply agreement with heska corporation to distribute nu.q® vet cancer screening test at the point of care with a $10 million upfront payment and up to $18 million based upon the achievement of near/mid-term milestones. under said agreement will receive ongoing additional revenue for key components and kits.
VNRX Ratings Summary
VNRX Quant Ranking